Current issue

October 2014

Volume 52

Issue 10

Welcome to Drug and Therapeutics Bulletin (DTB)

For 50 years, Drug and Therapeutics Bulletin (DTB) has provided rigorous and independent evaluations of, and practical advice on, individual treatments and the overall management of disease for doctors, pharmacists and other healthcare professionals.

DTB has always been wholly independent of the pharmaceutical industry, Government and regulatory authorities. DTB is also free of advertising and other forms of commercial sponsorship.

Suggest a topic

What topics would you like DTB to cover in future issues?

In terms of your prescribing practice, what are the key issues you face today? We want to ensure that we continue to provide you with the most relevant and up-to-date information. If you have any suggestions about topics or articles you would like to see published in DTB, please let us know.


DTB Podcasts

Listen to the latest DTB podcast, with Editor in Chief James Cave and Deputy Editor David Phizackerley discussing this month's issue:

October Podcast >>
Previous Podcasts >>

Taxing Medicines

The NHS prescription charge is ‘iniquitous’ and ‘outdated’ and should be scrapped, urges the Drug and Therapeutics Bulletin in an editorial published in this month’s issue.

Read the Editorial here >>

Read the Press Release here >>

DTB Select

Every month, DTB scans sources of information on treatments, disease management and other healthcare topics for key items to bring to our readers’ attention and help them keep up to date. To do this, we produce succinct, contextualised summaries of the information concerned. We also include comments on, for example, the strengths of the information, whether it contains anomalies, ambiguities, apparent error or omissions, or whether or how it affects current practice.

View DTB Select >>

CME/CPD articles

Read our educational articles and then test your knowledge on BMJ Learning:

View collection of educational articles >>

View the latest answers >>

All Trials

DTB supports the All Trials initiative calling for all trials to be registered and all results reported.